New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 23, 2014
07:44 EDTBMRNBioMarin survey shows strong Vimizim demand, says Leerink
Leerink said its survey of 14 physicians indicates "robust" demand and early commercial adoption of BioMarin's Vimizim. The firm believes physicians and patients are less critical of Vimizim's clinical profile than Wall Street. It reiterates an Outperform rating on BioMarin shares with a $90 price target.
News For BMRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2015
10:14 EDTBMRNOptions with decreasing implied volatility
Subscribe for More Information
April 9, 2015
10:48 EDTBMRNDeutsche compares PTC Therapeutics to Vertex, boosts target by $40
Subscribe for More Information
April 6, 2015
08:53 EDTBMRNSarepta risk/reward attractive, says Roth Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use